-transparent.png){kind=logo}
When a patient with non-Hodgkin's lymphoma (NHL) undergoes a relapse, immunological testing of malignant lymphocytes usually shows that the relapse cells are derived from the original tumor clone. We have observed a patient with a B cell lymphoma whose cells bore surface membrane IgG kappa at diagnosis and IgG lambda at clinical relapse 21 months later, during which time he had received multiple-drug chemotherapy. The shift from kappa to lambda light chain expression implies that the patient's apparent relapse was in fact due to the development of a second tumour. This may be another example of cytotoxic drug-induced carcinogenesis in a patient with a lymphoproliferative disorder.
R M Lowenthal, and
R W Harlow
May 1986,
Archives of pathology & laboratory medicine,
R M Lowenthal, and
R W Harlow
January 1987,
Archives of pathology & laboratory medicine,
R M Lowenthal, and
R W Harlow
March 1992,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
R M Lowenthal, and
R W Harlow
October 1986,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
R M Lowenthal, and
R W Harlow
December 1986,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
R M Lowenthal, and
R W Harlow
February 1993,
American journal of hematology,
R M Lowenthal, and
R W Harlow
September 1998,
Clinica chimica acta; international journal of clinical chemistry,
R M Lowenthal, and
R W Harlow
January 1991,
Terapevticheskii arkhiv,
R M Lowenthal, and
R W Harlow
February 1990,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
R M Lowenthal, and
R W Harlow
November 2005,
Clinical and diagnostic laboratory immunology,
